9713 Key West Ave., Suite 400
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
186 articles with MaxCyte, Inc.
MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that Shruti Abbato has joined the Company as Executive Vice President, Business Development for CARMA Cellular Therapies
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement.
MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients
CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential
MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology
MaxCyte, the global cell-based therapies and life sciences company, announces two presentations at the 5th Annual Cell & Gene Therapy Congress taking place 29-30 October in London, UK, which showcase the Company’s cell therapy technology.
MaxCyte announces that Director of Field Applications Scientists Christopher Mann, PhD, will present on “Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering” at the 2nd International Conference on Lymphocyte Engineering on Saturday 14 September at 9:50 a.m. BST.
MaxCyte announced that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia.
No dose-limiting toxicities or safety concerns observed in first cohort of treated patients
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced the launch of the new ExPERT™ technology platform.
MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Doug Doerfler, Chief Executive Officer, will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018, at 1:10 p.m. ET in New York City.
Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology
MaxCyte announced today that the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the Company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.
First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in ovarian cancer and peritoneal mesothelioma
Company to conduct Phase I clinical study of MCY-M11, a CAR therapeutic, in patients with ovarian cancer and peritoneal mesothelioma
MaxCyte and U.S. National Institutes of Health's National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
Under this agreement, MaxCyte's second signed with a U.S. NIH institute in the past year, the Company and the National Heart, Lung, and Blood Institute will explore development of new therapies for sickle cell disease using MaxCyte's gene-correction platform
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
MaxCyte, the global cell-based medicines and life sciences company, today announced that Linghong Li, PhD, Director, Cell Engineering, presented pre-clinical data at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Chicago on Friday, May 18, 2018, in which MaxCyte's non-viral cell engineering technology was used for CRISPR-mediated gene-correction of a mutation within the hemoglobin gene of cells from a sickle cell disease (SCD) patient.